skip to main content
ukmla 2026

Ménière's Disease

Episodic vertigo (20 min–12 h), fluctuating SNHL, tinnitus, and aural fullness — caused by endolymphatic hydrops. Betahistine for prophylaxis

ENTless-commonchronic
On this page
Condition details
ENT
less-common
6 min read
reviewed 2026-04-05
practice ukmla questions →

About This Page

This is a clinician-written, evidence-based summary aligned to the 2026 MLA Content Map. It is intended for medical students and junior doctors preparing for the UKMLA. Always cross-reference with NICE guidance, local protocols, and clinical judgement.

Key points

  • Triad: episodic vertigo (20 min–12 h) + fluctuating low-frequency SNHL + tinnitus + aural fullness
  • Caused by endolymphatic hydrops
  • Diagnosis: ≥2 vertigo episodes with audiometrically documented SNHL in affected ear
  • Acute: prochlorperazine (short course only). Prophylaxis: betahistine 16 mg TDS + low-salt diet
  • Refractory: intratympanic gentamicin or endolymphatic sac decompression
  • MRI IAM to exclude vestibular schwannoma

Overview

Ménière's disease is characterised by episodic vertigo, fluctuating SNHL (initially low-frequency), tinnitus, and aural fullness. Underlying pathology is endolymphatic hydrops. Typically unilateral at onset; bilateral in 25–40% over time.

Epidemiology

Affects 50–200 per 100,000 adults. Peak 40–60 years. Almost exclusively adults (<3% children). Significant QoL impact.

Clinical Features

Symptoms
Episodic rotational vertigo 20 min–12 h — spontaneous, NOT positional
Fluctuating hearing loss — initially low-frequency
Low-pitched roaring tinnitus
Aural fullness
Drop attacks (Tumarkin crisis) — sudden falls, late disease
Signs
During attack: horizontal nystagmus away from affected ear
Between attacks: examination may be normal
Rinne positive, Weber away from affected ear

Investigations

First-line
Pure tone audiometryLow-to-mid frequency SNHL — required for definite diagnosis
Second-line
MRI IAMExclude vestibular schwannoma
Specialist
ElectrocochleographyElevated SP/AP ratio supports hydrops — not routine
Caloric testingCanal paresis on affected side
1
Acute attack
  • Prochlorperazine 5–10 mg or cyclizine 50 mg — short course only
  • Anti-emetics if vomiting
2
Prophylaxis
  • Betahistine 16 mg TDS
  • Low-salt diet <1.5 g/day
  • Avoid caffeine, alcohol, nicotine
3
Vestibular rehabilitation
  • Physiotherapy for inter-attack imbalance
4
Refractory
  • Intratympanic gentamicin (chemical labyrinthectomy)
  • Intratympanic dexamethasone
  • Endolymphatic sac decompression
  • Labyrinthectomy (last resort, destroys hearing)

Complications

  • Permanent hearing loss: Progressive, eventually all frequencies, bilateral in 25–40%
  • Chronic imbalance
  • Tumarkin crisis: Drop attacks without LOC
  • Psychosocial impact
UKMLA Exam Tips
  • 1Ménière's: vertigo 20 min–12 h + SNHL + tinnitus + fullness — all SAME ear
  • 2BPPV = seconds, positional, NO hearing loss. Ménière's = minutes-hours, spontaneous, WITH hearing loss
  • 3Betahistine 16 mg TDS — standard UK prophylaxis
  • 4Low-frequency SNHL on audiogram = early Ménière's (vs high-frequency = presbyacusis)
  • 5Unilateral SNHL + vertigo → exclude vestibular schwannoma → MRI IAM
  • 6Tumarkin crisis: sudden drops without LOC — late-stage
practicetest your knowledge on Ménière's DiseaseApply what you've learnt with UKMLA-style questions from the iatroX Q-Bank — ENT and beyond.
open q-bank

Verified Sources & References

NICE CKS — Ménière's disease